CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Oliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández-Fernández, Thomas Forst, Juan Pablo Frias, James R. Gavin, Francesco Giorgino, Per Henrik Groop, Hiddo J.L. Heerspink, Stephan Herzig, Michael Hummel, George Huntley, Mahmoud Ibrahim, Baruch Itzhak, Stephan Jacob, Linong Ji, Mikhail KosiborodNebosja Lalic, Sofia Macieira, Rayaz A. Malik, Boris Mankovsky, Nikolaus Marx, Chantal Mathieu, Timo D. Müller, Kausik Ray, Helena W. Rodbard, Peter Rossing, Lars Rydén, Petra Maria Schumm-Draeger, Peter Schwarz, Jan Škrha, Frank Snoek, Frank Tacke, Bruce Taylor, Britta Tendal Jeppesen, Solomon Tesfaye, Pinar Topsever, Tina Vilsbøll, Xuefeng Yu, Eberhard Standl

Research output: Contribution to journalComment/debate

2 Scopus citations

Abstract

The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).

Original languageEnglish
Article number104
JournalCardiovascular Diabetology
Volume23
Issue number1
DOIs
StatePublished - Dec 2024
Externally publishedYes

Keywords

  • CGM
  • Cardiovascular disease
  • Chronic kidney disease
  • Diabetes
  • Finerenone
  • GLP-1 RA
  • Guidelines
  • Heart failure
  • MASLD
  • NAFLD
  • Obesity
  • SGLT2 inhibitor
  • Teplizumab

Fingerprint

Dive into the research topics of 'CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes'. Together they form a unique fingerprint.

Cite this